AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02040233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
Study NCT02343614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT03251144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to E/C/FTC/TAF daily
Description: If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months.
Study NCT02651103 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: Cerebral oxygenation monitor which is standard of care for this surgery.
Study NCT01321177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Description: Integrated program of treatments and services delivered by a coordinated team of providers that includes:~* education about schizophrenia and its treatment for the participants and their family members~* medication for symptoms and preventing relapse that uses a computerized decision support system~* strategies for managing the illness and building personal resilience~* help getting back to school or work using a supported employment/education model
Study NCT01321177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Care
Description: Standard mental health treatments and services offered at the local agency that may include :~* medication for symptoms and preventing relapse~* psychosocial therapy which may include a range of behavioral treatments and supportive services~* Case management
Study NCT03790137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine Hydrochloride
Description: Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.7 mg/kg/day, or a total maximum dose of 26 mg/day. The subject will remain on a dose of 0.7 mg/kg/day, 26 mg/day, or maximum tolerated daily dose through the end of the core study period.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CDVA
Description: Monocular and binocular Corrected Distance Visual Acuity (UDVA) was evaluated at all visits (preoperative, D1, M1, M3, M6 and M12), using the ETDRS chart.
Study NCT03826901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delgocitinib
Description: Cream for topical application
Study NCT02646800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Injection
Study NCT00914654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: inhaled formoterol
Description: Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
Study NCT01223755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
Study NCT01223755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
Study NCT01731028 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: Somatropin powder and solvent for solution for injection
Study NCT01236495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal morphine 0.3 mg
Description: spinal morphine 0.3 mg
Study NCT01236495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinal morphine 0.2 mg
Description: spinal morphine 0.2 mg
Study NCT01780467 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Role of dopamine
Study NCT01780467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role of dopamine
Study NCT04237350 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video recording for behaviors
Description: A domenstic apparatus, scenario, and procedure is applied to record all the behavioral phenotypes.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the mobile phone screen. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for about 3 minutes to ensure that behavioral phenotypes could be completely recorded.
Study NCT02720549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
Study NCT02720549 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: valvular surgery with bypass
Description: valvular surgery with bypass
Study NCT01617551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
Study NCT01617551 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
Study NCT00413049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 80/5 mg
Description: 1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
Study NCT00413049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: 1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
Study NCT03256227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Supported Prolonged Exposure
Description: The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
Study NCT03256227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Prolonged Exposure
Description: Standard Prolonged Exposure for PTSD as delivered in routine VA care.
Study NCT01470898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bispectral index monitoring
Description: A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
Study NCT00032227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Carpal Tunnel Release for Mild or Moderate CTS
Description: Either open or endoscopic surgery
Study NCT00032227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Carpal Tunnel Release for Mild or Moderate CTS
Description: Either open or endoscopic surgery
Study NCT00032227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Nerve Imaging for CTS
Description: New diagnostic test for CTS to directly image the median nerve
Study NCT00032227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MR Nerve Imaging for CTS
Description: New diagnostic test for CTS to directly image the median nerve
Study NCT00769496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 77-1931
Description: Lanthanum Carbonate (BAY 77-1931)
Study NCT00024154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00024154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00024154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01006954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microdose GnRh
Description: Microflare protocol in poor responders for IVF/ICSI
Study NCT01006954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flare up
Description: Flare up protocol in poor responders for IVF/ICSI
Study NCT00549497 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GW870086X
Study NCT00893217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: 250 mcg
Study NCT03687619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO-OP
Description: Interventions (from top to down) related to the development of fine-motor skills
Study NCT03687619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conductive Education
Description: Interventions (from down to top) related to the development of fine-motor skills
Study NCT03563794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII+Vildagliptin
Description: Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
Study NCT03563794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII(insulin Lispro)
Description: T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UIVA / DCIVA
Description: Uncorrected and Distance Corrected Intermediate Visual acuity (UIVA / DCIVA) was evaluated postoperatively at M1, M3, M6 and M12, using an intermediate chart from 67 cm.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UNVA / DCNVA
Description: Uncorrected and Distance Corrected Near Visual acuity (UNVA / DCNVA) was evaluated postoperatively at M1, M3, M6 and M12, using a near chart from 40 cm.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Manifest Refraction
Description: Manifest refraction was the monocular subjective refraction (Sph, Cyl, Axis) giving the best distance corrected visual acuity. It was measured at the screening visit and the follow-up visits Day 1, Month 1, Month 3, Month 6 and Month 12.
Study NCT01531491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rebreathing tube
Description: 750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
Study NCT01531491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No rebreathing tube (Nothing)
Description: 750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
Study NCT04013581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZD group
Description: Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
Study NCT04013581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT-2 group
Description: Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
Study NCT03532555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Acetate
Description: Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
Study NCT03532555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No supplemental zinc
Description: Infants will receive standard of care, which is currently no supplemental zinc
Study NCT01444521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan and cisplatin
Description: irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles.
Study NCT01988012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 162 milligram (mg) administered subcutaneously once weekly for 24 weeks
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IOP
Description: Intraocular pressure (IOP) was measured at all visits (preoperative, D1, M1, M3, M6 and M12), using a non-contact tonometer.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VADC
Description: Visual Acuity Defocus Curve (VADC) was taken monocularly at M3, monocularly and binocularly at M6 and binocularly at M12, using the Multifocal Lens analyzer - MLA application.
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSDC
Description: Contrast Sinsitivity Defocus Curve (CSDC) was taken under photopic conditions at M6 and M12, using the Multifocal Lens Analyzer - MLA application
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSV-1000
Description: Contrast Sensitivity was measured using the CSV-1000 with distance correction in place at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd). Measurements were taken under four different light conditions:~* Photopic (M3 monocular and binocular, M6 binocular and M12 monocular)~* Mesopic (M6 binocular)~* Photopic with backlight (M6 binocular)~* Mesopic with backlight (M6 binocular)
Study NCT06642779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear film stability
Description: Tear film stability was assessed at screening visit and at follow-up visits M1, M3, M6, and M12 using the non-invasive Tear break Up Time (TBUT) with fluorescein dye.
Study NCT06642779 — intervention group
Intervention type: DEVICE
Intervention: IOL implantation
Description: The investigational device (877PEY) and the comparator (877PAY) intraocular lens models were implanted, using sutureless, small-incision phacoemulsification surgery.
Study NCT02067156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Study NCT00893217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaseron (Interferon beta-1b, BAY86-5046)
Description: 500 mcg
Study NCT04027361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphetamine Extended Release (ER) Tablet 20 mg
Description: A single 20 mg dose of amphetamine ER Tablet, orally administered
Study NCT04027361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amphetamine Extended Release (ER) Tablet 20 mg
Description: A single 20 mg dose of amphetamine ER Tablet, orally administered
Study NCT02813499 — intervention group
Intervention type: OTHER
Intervention: CARE Rule
Description: Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
Study NCT02646553 — intervention group
Intervention type: OTHER
Intervention: Children refered to the obesity clinic
Description: Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
Study NCT01556841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax®
Description: Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity.
Study NCT01556841 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only.
Study NCT02814760 — intervention group
Intervention type: OTHER
Intervention: training of emergency professionals to acute stroke management
Description: The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~* Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~* Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization).
Study NCT03128203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, intranasally administrated
Study NCT03128203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline, intranasally administrated
Study NCT02488772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep mask
Study NCT02488772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care as decided by treating emergency physician
Study NCT02488772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear Plugs
Study NCT02331940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Study NCT02331940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Handihaler
Description: Inhalation via the HandiHaler once daily
Study NCT02331940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respimat
Description: Inhalation via the Respimat once daily
Study NCT00002956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
Study NCT02123966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus